Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Grp LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 60.75p 58.00p 63.50p - - - 781 12:02:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -2.8 -0.1 - 22.19

Salvarx Grp Share Discussion Threads

Showing 351 to 371 of 375 messages
Chat Pages: 15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
02/10/2018
08:09
Stig - are you old enough to remember Chesney Hawkes ?
dexdringle
02/10/2018
00:54
Portage has a history of creating value for its shareholders - one of its portfolio companies, Biohaven Pharmaceutical Holding Company Ltd ("Biohaven") (NYSE:BHVN), was the second largest biotech IPO on NASDAQ in 2017. Portage subsequently announced a distribution in specie of its stock in Biohaven to its shareholders. Their initial US$7 million investment was worth in excess of US$100 million at the time of the IPO in 2017, and has almost doubled since then. Biohaven is now worth approximately US$1.3 billion. Portage has provided seed capital to four other biotech companies and will seek to evaluate new opportunities. I am excited at the potential of working with the Portage team to progress our combined portfolio.
the stigologist
30/9/2018
19:34
This could just be one of the most profitable trades Jim Mellon has been involved in.
fig1
25/9/2018
06:28
Their website contact form doesn’t work so have had to ask broker to try to get it.
bscuit
15/9/2018
15:17
Bscuit, Did the company respond to your enquiry on that matter?
sweet karolina
13/9/2018
20:44
Much more important is taxation position of the distributed shares if not held in a ISA or similar.
bscuit
13/9/2018
17:20
What happens to 'free float' shares vis a vis Portage shares. Where do they end up? Can mm's profit from holding on to them?
fig1
13/9/2018
14:48
Seven separate sales of 713 shares each. This must be some kind of code !
dexdringle
12/9/2018
08:41
Portage website: "Toronto, Ontario, August 28, 2018 (PBT.U: CSE; PTGEF: OTC Markets) Portage Biotech Inc. ("Portage" or the "Company") wishes to announce that, further to its news release of August 14, 2018 announcing the proposed acquisition of SalvaRx Limited from SalvaRx Group plc, it has now submitted draft shareholder meeting materials to CSE for review. Until the meeting materials have been approved by CSE for distribution, however, trading in the shares of Portage will remain halted. Upon clearance of the meeting materials, a further announcement will be made regarding the meeting date and a trade resumption date" How long does it take the Canadian Stock Exchange to approve materials created to be used in a shareholder meeting? I fear this is all going to end in disappointment....
dexdringle
09/9/2018
21:44
....I'm sure it will (disappoint)....
dexdringle
09/9/2018
21:18
It's 20th October ladies and gentlemen. Let's hope Intensity don't disappoint. Fig.
fig1
07/9/2018
08:48
Is it "post something completely irrelevant" day ?
dexdringle
07/9/2018
08:40
htTps://twitter.com/Stockonomist/status/1037963927072788480?s=19
the stigologist
05/9/2018
16:39
"Crazy low valuation".....well only if the science works. Otherwise it is worth £0.....
dexdringle
03/9/2018
11:44
Crazy low valuation I still expect deal to be viewed positively in North America so the existing discount will simply become bigger and bigger
the stigologist
29/8/2018
01:36
hTtp://www.stockhouse.com/news/press-releases/2018/08/28/portage-provides-update-on-proposed-acquisition-of-salvarx
the stigologist
29/8/2018
01:35
Update re proposed disposal and demerger Further to the announcement of 14 August 2018 relating to the proposed disposal of the Company's 94.2 per cent. interest in its subsidiary SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company has been informed that the Portage shareholder circular has now been submitted to the Canadian Securities Exchange ("CSE") for review. Following completion of the CSE review, both Portage and the Company will publish their respective shareholder circulars and a further announcement will be made by the Company.
the stigologist
27/8/2018
09:14
If a startup company can be valued at $10 billion on just 40 patients data the potential for Intensity to be a $1 billion dollar company in the near future can't be dismissed. The Insiders clearly think we are onto something massive.
the stigologist
27/8/2018
09:12
These are mind boggling numbers... " The investor community is also optimistic about this sector with record amounts of venture money flowing into startups this past year. In fact, in February 2018, BMS recorded the largest upfront payment for a license in history. They paid US$3.6 billion for 35% of the profits on Nektar's immunotherapy after seeing data on approximately 40 patients."
the stigologist
26/8/2018
12:46
One does get the impression that ducks are being lined up in a row. Fig.
fig1
26/8/2018
11:30
Agree Stig. Intensity hasn’t tweeted since Dec 2017, now they tweet every day. Take the hint
jonesyboy 27
Chat Pages: 15  14  13  12  11  10  9  8  7  6  5  4  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20181016 18:55:47